We all know that Technology Transfer Offices (TTOs) are essential for increasing the impact of university research and providing opportunities for financial gain of research-based innovations. The performance of a TTO is often measured by the annual number of patent applications, license agreements and spin-offs.
The process of filing a patent application must be considered carefully, since a substantial expenditure is made up-front and often before any commercial interest is established. Also, the patenting process is lengthy with costs rapidly increasing during the grant process. When commercial interest for a patent cannot be established, many of these university patents are not continued and any initial expenditure is never regained. By contrast, licencing your reagents can still protect your intellectual property but has minimal up-front costs and can often outlast the life of a patent.
TTOs are always looking for ways to maximise the number of commercially-viable patents and associated license agreements.
Life Science Research tools – Small but mighty?
Commercialising your research tools can provide a long-term revenue stream for your university, with little to no costs outlaid. This is because your research tools:
Can be commercialised without any patent rights
Research tools can be made available for research use which can provide a financial return. Whether a research tool once had a patent, or never did, we can make these tools available through a license agreement that protects your ownership rights, provided they were generated by researchers at your university. Find out how Ximbio can support you through the entire commercialisation process.
Can be commercialised for research use at the same time as searching for therapeutic partners
Life science reagent commercialisation is often a low priority for TTOs because efforts are best spent on higher-value therapeutic innovations. By partnering with Ximbio your university research tools can be made available to the wider scientific research community without jeopardising your hunt for therapeutic licensees.
Can be commercialised at no cost to your institute or inventing scientists
Ximbio are a non-profit and so we, like you, have a similar mission to increase impact from research. By working with us, there is no cost up-front to your university and we operate on a revenue share basis. We work as an extension of your TTO office to identify, source and store your research reagents.
Once stored correctly, can provide a constant income over decades
Reagents can provide you with consistent royalty rates for years to come. Some of the reagents on our portfolio have been generating revenue for their inventing researchers and institutes for decades and still provide revenue today. Meet Anti-CD3 [UCH-T1] – this was created in 1981 by Professor Peter Beverley at Imperial College, London. Since then it has been widely used in numerous different experiments and is regular cited in research papers. It is also one of our most popular reagents, receiving regular licensing requests and providing a regular income stream for its inventor and the inventing institution.
Find out more about Anti-CD3 [UCH-T1]
Start your reagent commercialisation journey
Commercialising your reagents, when done efficiently, can be a simple yet effective route to generate income to supplement your current revenue streams. Together, we can ensure you have the right support to commercialise your reagents.